Core Viewpoint - Albemarle Corporation (ALB.US) has announced two equity sale agreements totaling approximately $660 million, marking a strategic shift to focus on its core lithium and bromine businesses [1] Group 1: Equity Sale Agreements - Albemarle will sell 51% of its Ketjen refining catalyst solutions business to KPS Capital Partners and transfer its 50% stake in the European catalyst joint venture Eurecat to Axens [1] - Post-transaction, Albemarle and KPS Capital Partners will hold 49% and 51% stakes in Ketjen, respectively [1] - Albemarle will retain 100% ownership of Ketjen's high-performance catalyst solutions business (PCS), including the PCS production facility located in Pasadena, Texas [1] Group 2: Business Focus and Use of Proceeds - Ketjen is recognized as a global manufacturer of advanced catalyst solutions, with applications in petrochemicals, transportation, construction, and agriculture [1] - The funds obtained from these transactions will be used to reduce debt and for general corporate purposes, aligning with the company's strategic focus [1]